The incidence of C. diff has been on the rise in recent years, and the emergence of an especially severe strain of the bacteria has increased the need for better detection and prevention ...

Researchers have identified two distinct mechanisms of drug resistance in C. difficile, but its ability to withstand antibiotics comes with downsides for the bacteria.

We do not underestimate the challenges in sampling and attributing C. difficile VOCs from faecal samples,” said Prof. Paul Monks, department of chemistry, University of Leicester and a study author.

C. diff causes about half a million infections in the U.S. each year, according to the Centers for Disease Control and Prevention. Factors that increase risk of C. diff infection include ...

University of Houston. "Treatment for deadly superbug C. diff may be weakening." ScienceDaily. ScienceDaily, 25 April 2024. <www.sciencedaily.com / releases / 2024 / 04 / 240425131603.htm>.

Arianna Miles-Jay, a postdoctoral fellow in Dr. Snitkin's lab, analyzed the over 1,100 patients in the study, and found that a little over 9% were colonized with C. diff.

The surprising origin of a deadly hospital infection C. diff may not result from transmission, but from within the infected patient themselves Date: September 18, 2023 Source: Michigan Medicine ...

Vancomycin has long been the go-to antibiotic of choice against C. difficile, with its use jumping 54% in the past six years, according to Garey and colleagues.

More than 450,000 C. diff infections are reported in the United States each year, leading to as many as 30,000 deaths, according to public health estimates.

Research by the University of Plymouth has showed spores of Clostridioides difficile, commonly known as C. diff, are completely unaffected despite being treated with high concentrations of bleach ...

Fecal microbiota transplant might be considered for first-line treatment of Clostridioides difficile (C. diff), based on noninferiority findings from a randomized, open-label trial. A similar ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research ...